HIMS Share Price Performance
US$0
-27.60 (-100.00%)
Price US$0
Fair ValueUS$46.67
Share Pricen/a
Hims & Hers Health, Inc. Stock Price
- 5 Narratives written by author
- 10 Comments on narratives written by author
- 859 Fair Values set on narratives written by author
HIMS Community Narratives
AN
Fair Value US$46.67 22.8% undervalued intrinsic discount
Telehealth And Hormonal Health Will Transform Global Markets
12users have liked this narrative
0users have commented on this narrative
216users have followed this narrative
AN
Fair Value US$28 28.7% overvalued intrinsic discount
Mounting Regulatory Costs And Intensifying Telehealth Competition Will Undermine Prospects
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
BL
Fair Value US$86.09 58.1% undervalued intrinsic discount
Hims: The Platform Powering Personalised Healthcare
29users have liked this narrative
9users have commented on this narrative
139users have followed this narrative
Hims: The Platform Powering Personalised Healthcare
Summary Platform Play, Not a Pill Company: Hims is building the infrastructure for personalised, direct-to-consumer healthcare across diagnostics, treatment, and prevention, similar to what Amazon did for retail and Spotify for music. Strong Fundamentals with Operating Leverage: The company is growing fast, generating free cash flow, and scaling efficiently, with rising margins, high retention, and zero debt.Read more
29users have liked this narrative
9users have commented on this narrative
139users have followed this narrative
BL
US$86.09
58.1% undervalued intrinsic discount
BlackGoat Fair Value
Revenue growth
22% p.a.
Profit Margin
15%
Future PE
50x
Share price in 2030
US$138.65
Hims & Hers are taking grip on Telemedicine
Catalysts Financial Performance : In 2023 , Hims & Hers reported impressive financial results: Revenue : Reached $872.0 million , reflecting a 65% year-over-year increase. Net Income : Achieved $1.2 million in Q4 2023.Read more
5users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
WA
US$17.15
110.2% overvalued intrinsic discount
WallStreetWontons Fair Value
Revenue growth
100% p.a.
Profit Margin
1%
Future PE
20x
Share price in 2029
US$25.13
Telehealth And Hormonal Health Will Transform Global Markets
Key Takeaways Diversification into new health categories, innovative tech integration, and international expansion are expected to drive sustained growth, operational efficiency, and increased global market share. Strong user adoption, enhanced personalized offerings, and industry trends toward telehealth position the company for higher recurring revenue and long-term earnings stability.Read more
12users have liked this narrative
0users have commented on this narrative
216users have followed this narrative
AN
US$46.67
22.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
17.12% p.a.
Profit Margin
8.59%
Future PE
48.11x
Share price in 2028
US$56.98
Mounting Regulatory Costs And Intensifying Telehealth Competition Will Undermine Prospects
Key Takeaways Regulatory and consumer pressures threaten user growth, pricing power, and margins, especially amid expanding generic competition and industry shifts toward price transparency. Intensifying data privacy laws and escalating competition challenge digital marketing effectiveness, raise compliance and customer acquisition costs, and complicate international expansion and long-term earnings.Read more
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$28
28.7% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
15.17% p.a.
Profit Margin
8.74%
Future PE
31.69x
Share price in 2028
US$34.05
Telemedicine And AI Integration Will Redefine Digital Healthcare
Key Takeaways Vertical integration in diagnostics and advanced compounding boosts personalized care, user retention, and unlocks new, durable revenue streams. Investments in AI, data platforms, and global expansion support scalable, automated healthcare delivery, positioning the company for higher margins and sustained earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$82.55
56.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
27.19% p.a.
Profit Margin
8%
Future PE
75.77x
Share price in 2028
US$100.4
Snowflake Analysis
Hims & Hers Health, Inc. Key Details
About HIMS
- Founded
- n/a
- Employees
- 1637
- CEO
- WebsiteView website
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company’s curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
